Today on Drug Discovery & Development
Why Schedule III cannabis could be a win for Big Pharma
Fifty years of restricted research may be coming to an end. Reports that President Trump plans to direct cannabis rescheduling would finally open federally-funded clinical trials for cannabinoid therapeutics, and force the industry to answer questions it’s long avoided. Pharma companies like Jazz (Epidiolex) and AbbVie already have cannabinoid programs. This could accelerate M&A or…
Ajinomoto CELLiST Korea launches CELLiSTTM AAV production supplement 1 to improve gene therapy manufacturing efficiency
Ajinomoto, founded in 1909 after chemist Kikunae Ikeda isolated glutamate from kelp broth and commercialized it as MSG, has evolved from seasoning to cell culture media over more than a century Now, its Korean subsidiary Ajinomoto CELLiST Korea, which focuses on cell culture media development and manufacturing, announced the launch of CELLiSTTM AAV Production Supplement…
Drug Discovery and Development See More >
Sai Life Sciences to double process R&D capacity with new Hyderabad facility
New CMC Process R&D center will add peptide and oligo-intermediate capabilities, expand analytical and formulation labs and target completion by September 2026. Sai Life Sciences plans to build a 100,000-sq-ft CMC Process R&D center at its integrated R&D campus in Hyderabad, aiming to double its process R&D capacity by September 2026. The project adds dedicated…
Sponsored Content See More >
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
How tailored qPCR assays can unlock microbiome and precision medicine potential Sponsored by Diversigen, Inc. Quantitative Polymerase Chain Reaction (qPCR) — also known as real-time PCR — is a molecular…
Innovations in Baculovirus–Insect Cell Expression SystemsThe baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)—remains a crucial technology for…
Genomics/Proteomics See More >
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
St. Jude pioneers gene editing and structural biology to advance pediatric research
Infectious Disease See More >
Vaccines, autism and America: A stress test for public health standards
Vaccines, autism and America: A stress test for public health standards The CDC recently overhauled its “Autism and Vaccines” webpage, telling readers that the familiar claim that “vaccines do not cause autism” is not evidence based because studies have not ruled out the possible effect from infant vaccines. It goes on to note that “correlation…
Oncology See More >
Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer
You said:Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer Giredestrant, an experimental oral selective estrogen receptor degrader, reduced the risk of invasive disease recurrence or death by 30% compared with standard hormone therapy in a phase 3 trial of more than 4,100 patients with early-stage, hormone receptor-positive, HER2-negative breast cancer.…
